

Huntington Disease (HD)

BN40697 - A study to look at tominersen safety over 15 months in people with Huntington's disease

An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT03342053 ISIS 443139-CS2
BN40697

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT03342053 ISIS 443139-CS2 BN40697
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥25 Years

Healthy Volunteers
No
